Abstract

Background: Autoimmune hepatitis (AIH) is a chronic and aggressive liver disease that rapidly evolves into cirrhosis and end-stage liver disease if not timely diagnosed and treated with immunosuppressive therapy. AIH is classified into type 1 and type 2 according to the autoantibody pattern, with smooth muscle antibodies and/or antinuclear antibodies as serological markers of AIH-1, while antiliver cytosol antibody type 1 and/or antiliver/kidney microsomal antibody type 1 characterize type 2 AIH, which mainly affects children, including infants, and adolescents. Case Summary: We describe a case of type 2 AIH, clinically onset in a 34-year-old woman with decompensated cirrhosis. Only a thorough analysis of the autoantibody profile allowed for a diagnosis of an AIH-2 evolved into cirrhosis. The patient received a moderate corticosteroid therapy without achieving optimal disease control. We discuss the controversial decision of whether or not to treat the patient with immunosuppressive therapy, which should be balanced with the potential risk of infectious and other complications. A review of the literature on the management of patients with autoimmune cirrhosis is also presented. Conclusions: AIH-2 can be clinically onset in adult patients with cirrhosis and its complications, without being preceded by major clinical signs. Due to the difficult management of cirrhosis with immunosuppressive treatments, a patient-tailored strategy with a case-by-case approach is needed to prevent major complications such as infections, potentially precluding liver transplantation the only curative therapy.

Highlights

  • Licensee MDPI, Basel, Switzerland.Autoimmune hepatitis (AIH) is a chronic and severe liver disease of unknown etiology, which mainly affects young women and can quickly develop into cirrhosis and end-stage liver disease if not timely diagnosed and treated with immunosuppressive therapy [1,2,3].AIH is historically classified into type 1 and type 2 based on the autoantibody profile, with antinuclear antibodies (ANA) and/or smooth muscle antibodies (SMA) as serological markers of AIH type 1, while liver/kidney microsomal type 1 (LKM1) autoantibody and/orAttribution (CC BY) license.liver cytosol antibody type 1 (LC1) autoantibody characterize AIH type 2

  • In the 1990s, on the basis of the autoantibody profile, AIH was classified into three main types: type 1 characterized by ANA and/or SMA positivity, type 2 marked by anti-LKM1 anti-LC1, and type 3 exhibiting anti-SLA antibodies

  • Into two forms, type 1 and type 2, seems to have a certain relevance in pediatric settings: anti-LKM1 positive forms are characteristic of children with higher levels of bilirubin and transaminases at onset who more frequently present fulminant liver failure, while the presence of cirrhosis in the baseline biopsy and a severely compromised liver function is more frequent in AIH-1 [7,8]

Read more

Summary

Introduction

Licensee MDPI, Basel, Switzerland.Autoimmune hepatitis (AIH) is a chronic and severe liver disease of unknown etiology, which mainly affects young women and can quickly develop into cirrhosis and end-stage liver disease if not timely diagnosed and treated with immunosuppressive therapy [1,2,3].AIH is historically classified into type 1 and type 2 based on the autoantibody profile, with antinuclear antibodies (ANA) and/or smooth muscle antibodies (SMA) as serological markers of AIH type 1, while liver/kidney microsomal type 1 (LKM1) autoantibody and/orAttribution (CC BY) license (https://creativecommons.org/licenses/by/ 4.0/).liver cytosol antibody type 1 (LC1) autoantibody characterize AIH type 2. Autoimmune hepatitis (AIH) is a chronic and severe liver disease of unknown etiology, which mainly affects young women and can quickly develop into cirrhosis and end-stage liver disease if not timely diagnosed and treated with immunosuppressive therapy [1,2,3]. AIH is historically classified into type 1 and type 2 based on the autoantibody profile, with antinuclear antibodies (ANA) and/or smooth muscle antibodies (SMA) as serological markers of AIH type 1, while liver/kidney microsomal type 1 (LKM1) autoantibody and/or. AIH is classified into type 1 and type 2 according to the autoantibody pattern, with smooth muscle antibodies and/or antinuclear antibodies as serological markers of AIH-1, while antiliver cytosol antibody type 1 and/or antiliver/kidney microsomal antibody type 1 characterize type 2 AIH, which mainly affects children, including infants, and adolescents.

Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call